Slow-Motion Analysis of Repetitive Tapping (SMART): a pilot study of a new measurement of bradykinesia
Objective: To assess repetitive tapping movements (RTM) using a slow motion camera and compare them with a clinician visual impression in people that have been…What connectivity tells us about neurodegeneration in Huntington disease? A fMRI study
Objective: Our study investigated the impact of Huntington disease (HD) on brain connectivity, through resting-state (RS) fMRI, among the most critical regions associated with physiopathology.…Reliability, feasibility and validity of a novel digital monitoring platform assessing cognitive and motor symptoms in people with Stage I and II Huntington’s disease (HD)
Objective: To determine the reliability and convergent validity of a novel digital monitoring platform offering objective, daily assessment of cognitive and motor symptom severity in…Brain MRI Volume Changes after 12 months laquinimod treatment of Huntington disease (LEGATO-HD)
Objective: To explore the effect of laquinimod on brain volume in patients with Huntington Disease (HD). Background: Volume loss in caudate and other brain regions…Application of the “5-2-1” Screening Criteria in Advanced Parkinson’s Disease Patients Treated with Levodopa-Carbidopa Intestinal Gel: Interim Analysis from the DUOGLOBE Study
Objective: Evaluate if patients fulfill the recently developed “5-2-1” screening criteria for advanced Parkinson’s Disease (APD)[1] prior to treatment with levodopa-carbidopa intestinal gel (LCIG) and…High Dose Botulinum Toxin Therapy: Safety, Benefit and Endurance of Efficacy
Objective: To assess safety, therapeutic response and long-term benefit of higher dose Onabotulinum toxin A (OnaA). Background: Botulinum toxin therapy is a powerful tool for…Influence of disease duration in the efficacy response of Parkinson’s disease patients with motor fluctuations: post-hoc analysis from combined BIPARK-I and II
Objective: To evaluate the impact of disease duration on the efficacy of opicapone (OPC) in levodopa-treated Parkinson’s Disease (PD) patients with motor fluctuations. Background: OPC,…Incidence of treatment-emergent adverse events in Parkinson’s disease patients according to baseline body mass index: post-hoc analysis from double-blind combined BIPARK-I and II data.
Objective: To evaluate the incidence of treatment-emergent adverse events (TEAEs) in levodopa-treated Parkinson’s Disease (PD) patients with motor fluctuations and taking opicapone (OPC). Background: OPC…A Phase 2 Study of the Efficacy, Durability and Safety of Ampreloxetine (TD-9855), a Norepinephrine Reuptake Inhibitor, Given Once-daily to Treat Neurogenic Orthostatic Hypotension (nOH) in Subjects with Synucleinopathies
Objective: To assess the efficacy and durability using validated symptom questionnaire OHQ, and safety of ampreloxetine, given once-daily to treat neurogenic orthostatic hypotension (nOH) in…Oligomeric Alpha-synuclein in Erythrocyte Membrane in Early Parkinson’s Disease
Objective: To determine whether α-synuclein concentrations in the cell membrane and cytoplasm of erythrocytes are altered in PD patients and to evaluate their potential role…
- « Previous Page
- 1
- …
- 209
- 210
- 211
- 212
- 213
- …
- 217
- Next Page »